Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Executive Summary

Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.

Advertisement

Related Content

Keeping An Eye On Regeneron: What's Next To Drive Growth
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics
PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Amgen Faces New ICER Roadblock To Repatha Reimbursement
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
US advisers endorse PCSK9 Praluent, but limited population

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel